How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms
The Journal of Clinical Pharmacology – January 16, 2014
Source: OpenAlex
Summary
MDMA, used by over 16 million Americans, offers euphoric effects like elevated mood and enhanced social bonding. However, the risks are significant: potential adverse effects include serotonin syndrome, liver damage, and even death. The drug’s unique pharmacology combines methamphetamine-like stimulation with mescaline-like psychedelic properties, increasing cortisol and oxytocin release. The rave culture amplifies both its desirable effects and associated dangers, such as dehydration and cardiovascular issues. Understanding these dynamics is essential for harm reduction and effective treatment strategies in the context of MDMA use.
Abstract
Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) is an agent of abuse that has been used by over 16 million Americans. Increased energy, elevated mood, bonding with others, and psychedelic effects are desired effects while liver damage, extended depressed mood, sexual assault, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events, arrhythmias, and death are possible adverse effects. These desirable and adverse effects of MDMA are extensions of its fascinating pharmacologic and pharmacokinetic profile. In addition to methamphatemine like effects, MDMA also has mescaline like effects and increases the release of cortisol, oxytocin, and antidiuretic hormone. The desirable effects of MDMA are accentuated by the rave or electronic dance music scene where warm temperatures, vigorous dancing, loud music, and light shows accentuate some of the responses. However, the same environment increases the risk of certain harms. Knowledge of the constellation of these factors is needed for education, prevention of harm, and treatment.